Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.39 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | NPR1 | P16066 | 2/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5107465 | 0.89 | CTNNB1 (0.47) | NAMPTCTNNB1TCF7L2MKNK1MKNK2 | |
| SCHEMBL5116006 | 0.85 | GAA (0.43) | NTRK1MAP4K4 | |
| SCHEMBL5122180 | 0.79 | CA1 (0.46) | MKNK1MKNK2HPGDTTK | |
| SCHEMBL5116226 | 0.79 | NTRK1 (0.42) | MEN1KMT2ANTRK1HPGD | |
| SCHEMBL5114918 | 0.77 | RECQL (0.42) | CTNNB1TCF7L2RAB9A | |
| SCHEMBL5116297 | 0.77 | ARNT (0.39) | MEN1KMT2ANTRK1MAP4K4 | |
| SCHEMBL3334259 | 0.76 | CTNNB1 (0.53) | CTNNB1TCF7L2MCHR1NPR1SSTR5 | |
| SCHEMBL5115933 | 0.76 | SGK1 (0.34) | MEN1RAB9AKMT2ANTRK1HPGD | |
| SCHEMBL5116366 | 0.75 | MAP4K4 (0.36) | NTRK1MAP4K4MAPK14 | |
| SCHEMBL823680 | 0.75 | MKNK1 (0.49) | MEN1RAB9AKMT2AMKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729089-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729089-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729089-B2 | Pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| WO-2008077651-A1 | PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182870-A1 | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, DPYD, PNP | NAMPT 106/4885CTNNB1 1384/4885TCF7L2 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.